前沿速览044期| CAR-T治B淋 前沿览新知
01
CSF1R（+）髓系单核细胞促使侵袭性B细胞淋巴瘤对CAR-T细胞耐药
CSF1R(+) myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma
第一作者：Stahl D
Cancer Cell (IF=48.8). 2025 Jun 10:S1535-6108(25)00222-3.
全文网址：https://www.sciencedirect.com/science/article/pii/S1535610825002223?via%3Dihub
02
通过补充Akkermansia菌属调节肠道菌群以增强CAR-T细胞效力
Gut microbiota modulation through Akkermansia spp. supplementation increases CAR-T cell potency
第一作者：Marcos-Kovandzic L
Cancer Discov (IF=30.6). 2025 Jun 11.
全文网址：https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-24-1230/762930/Gut-microbiota-modulation-through-Akkermansia-spp
03
CD19 CAR-T细胞治疗系统性红斑狼疮患者和B细胞淋巴瘤患者的安全性特征比较
Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma
第一作者：Müller F
Blood (IF=21.1). 2025 Jun 12:blood.2025028375.
全文网址：https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2025028375/537757/Comparison-of-the-safety-profiles-of-CD19?redirectedFrom=fulltext
04
CAR-T细胞治疗复发/难治性LBCL老年患者的益处与挑战
CAR-T cell therapy in older adults with relapsed/refractory LBCL: benefits and challenges
第一作者：Shune L
J Immunother Cancer (IF=10.3). 2025 Jun 5;13(6):e009793.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/pmid/40480655/
05
一种新型全人源CD19/CD22双靶向环状CAR-T细胞治疗复发/难治性B细胞非霍奇金淋巴瘤的疗效与安全性
Efficacy and safety of a novel CD19, CD22 dual-targeted fully human loop bi-CAR-T for the treatment of relapsed/refractory B cell non-Hodgkin lymphoma
第一作者：Wang H
J Transl Med (IF=6.1). 2025 Jun 5;23(1):630.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC12142955/
06
CAR-T细胞疗法为复发或难治性成人伯基特淋巴瘤患者进一步巩固治疗提供了机会
CAR T- cell therapy provides an opportunity for further consolidation treatment for relapsed or refractory adult Burkitt lymphoma patients
第一作者：Liu R
Front Oncol (IF=3.5). 2025 May 23;15:1566938.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC12141207/
07
CAR-T细胞治疗弥漫大B细胞淋巴瘤后 (18)F-FDG PET/CT早期评估的预后价值
Prognostic value of early post-treatment (18)F-FDG PET/CT in diffuse large B-cell lymphoma patients receiving chimeric antigen receptor T-cell therapy
第一作者：Mirshahvalad SA
Cancer Imaging (IF=3.5). 2025 Jun 8;25(1):70.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC12147336/
08
SARS-CoV-2感染对接受CAR-T细胞治疗的复发/难治性大B细胞淋巴瘤患者结局无影响
SARS-CoV-2 infection does not affect the outcome of patients with relapsed/refractory large B-cell lymphoma treated with CAR T-cell therapy
第一作者：Gentilini M
Ann Hematol (IF=3.0). 2025 Jun 4.
全文网址：https://link.springer.com/article/10.1007/s00277-025-06425-8
09
滤泡性淋巴瘤患者（无论有无组织学转化）接受嵌合抗原受体T细胞治疗的回顾性队列研究
A retrospective cohort study of chimeric antigen receptor T-Cell therapy in follicular lymphoma patients with or without histological transformation
第一作者：Wang J
Ann Hematol (IF=3.0). 2025 Jun 2.
全文网址：https://link.springer.com/article/10.1007/s00277-025-06428-5
10
肥胖对弥漫性大B细胞淋巴瘤患者接受CAR-T细胞疗法的影响
Impact of Obesity on Patients with Diffuse Large B-Cell Lymphoma Receiving CAR T-Cell Therapy
第一作者：Tan JY
Oncology (IF=2.5). 2025 Jun 13:1-11.
全文网址：https://karger.com/ocl/article-abstract/doi/10.1159/000545933/928833/Impact-of-Obesity-on-Patients-with-Diffuse-Large-B?redirectedFrom=fulltext
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2025.6-16 valid until 2027.6
供稿与审核：临床开发与医学部